<DOC>
	<DOCNO>NCT00606970</DOCNO>
	<brief_summary>Project : Assessment safety dietary supplement lactobacillus ferment extract cancer patient undergo chemotherapy Nausea vomit significant cause nutritional depletion result deterioration physical mental status . Support gastrointestinal function may alleviate nausea vomit chemotherapy reduce discomfort experienced patient allow good tolerance treatment . This study ass orally administer Seigen alpha EV chemotherapy safety effect nutritional depletion derive chemotherapy . It also look effect immune system patient undergoing chemotherapy .</brief_summary>
	<brief_title>Safety Assessment Lactobacillus Fermented Extract Cancer Patients Undergoing Chemotherapy</brief_title>
	<detailed_description>Randomization Treatment : The subject distribute three cancer category ( breast , lung , colon ) , randomize centralized randomization list cancer category assign unique identification number temporal order recruitment . Using randomization minimization method , subject allocate treatment placebo , 15 treatment group placebo group , total 30 subject 3 cancer . This study utilize double-blind . Placebo : The placebo identical packaging appearance treatment . Identification placebo vs. Seigen alpha EV unique packaging code . Patients study doctor blind identification interpretation . Treatment : Treatment maximum 3 month . The dosage study supplement follow : Subjects instruct take 1 packet ( 6 gram ) 3 time daily total daily dosage 3 packet ( 18 gram ) . Each packet clearly mark breakfast , lunch , supper . The content packet dissolved water liquid take orally morning , noon , even . Subjects require return unused packet study doctor end month . Assessment : Usual clinical test therapeutic monitor usual treatment patient perform . In addition , quantitative qualitative parameter measure start treatment 1 , 2 , 3 month : 1 . Toxicity assessment use National Cancer Institute Common Toxicity Criteria ( NCI CTC ) : total WBC , total lymphocyte count , hemoglobin , platelet count , nausea , vomit , diarrhea , loss appetite , weight loss , anorexia , urticaria , fatigue , muscle weakness headache . ( Refer Document 1 Toxicity Assessment ) 2 . Self-assessment quality life perform use European Organization Research Treatment Cancer ( EORTC ) QLQ-C30 ( version 3 ) . The treat physician summarize patient quality life use Karnofsky performance scale . 3 . Additional blood test 10 colon CA subject ( 5 treatment , 5 placebo ) Molecular marker NFÎºB mediate signal transduction pathway gene ( n=84 ) measure 10 subject colon cancer . A sample less 5 ml use PAXgene Blood RNA Tubes ( Qiagen , Cat . No . 762115 ) collect subject . Shipment overnight least 10 lbs ice block ( blue wet ) SuperArray Bioscience Frederick , MD 21704 . Baseline repeat one , two three month .</detailed_description>
	<criteria>Eligible subject give write informed consent prior participation They must life expectancy great 6 month They must biopsy confirmed primary breast , colon lung cancer They receive standard chemotherapy accordance American Society Clinical Oncology ( ASCO ) standard least one month remain chemotherapy course They must Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 2 treated outpatient . Subjects must age 18 75 year age . Subjects must able communicate English . Have receive radiotherapy within last 4 week Have acute gastrointestinal problem e.g . acute gastrointestinal infection , gastric duodenal ulcer , history bowel obstruction , diverticulitis , Crohn 's disease , ulcerative colitis , chronic diarrhea Presence clinical evidence CNS metastases Receiving corticosteroid Have severe concomitant disease Have severe dysphagia , esophagitis xerostoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Chemotherapy</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Colon Cancer</keyword>
	<keyword>Lung Cancer</keyword>
</DOC>